---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-108292"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:47:32.084061+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma reports Q4 net income of $1.6M on $21.9M collab revenue from ImmunoScape; cash $27.1M

## Summary
- Net income $1.585M ($0.01 EPS) in Q4 2025 vs net loss $9.496M in Q4 2024; full-year net loss $26.6M vs $40.7M.
- Collaboration revenue $21.9M in Q4 vs $1.6M; primarily from $9.5M upfront from ImmunoScape deal, with $5M due Nov 2026.
- R&D expenses $16.5M (up from $7.2M) on CUE-401 mfg and ImmunoScape-related costs; G&A $3.5M (down from $4.0M).
- Appointed Lucinda Warren CFO; raised $10.2M net in public offering; cash $27.1M at Dec 31, 2025.
- Advanced CUE-401 autoimmune drug toward IND; reported preclinical safety data; plans Virtual R&D Day.

## SEC filing metadata
- accession: 0001193125-26-108292
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312526108292/0001193125-26-108292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312526108292/cue-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-108292
- JSON: https://secwatch.observer/filing/0001193125-26-108292.json
- Plain text: https://secwatch.observer/filing/0001193125-26-108292.txt

## Key facts
- Earnings Releases
  Cue Biopharma, Inc. reported the year ended December 31, 2025 results: revenue $27.5 million.
  - Period: the year ended December 31, 2025
  - Revenue: $27.5 million
  - Result: reported results
  source text: The Company reported collaboration revenue of $27.5 million and $9.3 million for the years ended December 31, 2025 and 2024, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526108292/0001193125-26-108292-index.htm
- Earnings Releases
  Cue Biopharma, Inc. reported the three months ended December 31, 2025 results: revenue $21.9 million.
  - Period: the three months ended December 31, 2025
  - Revenue: $21.9 million
  - Result: reported results
  source text: The Company reported collaboration revenue of $21.9 million and $1.6 million for the three months ended December 31, 2025 and 2024, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526108292/0001193125-26-108292-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.